Potenza Therapeutics management team is highly experienced in the field of immuno-oncology and drug development. Our goal is to build a leading biotechnology company translating scientific breakthroughs in cancer immunology to discover life-saving medicines for the treatment of human cancer.

Daniel J. Hicklin, PhD - President and CEO

Daniel Hicklin brings to Potenza over 25 years of biopharmaceutical research and operations experience with particular expertise in oncology drug development. Dr. Hicklin co-founded Potenza in 2014 and is the company’s President and CEO. He has served as a Managing Director at the life sciences venture capital investment firm MPM Capital since 2014 and is also a board member of Tizona Therapeutics and Harpoon Therapeutics.  Previously, Dr. Hicklin served as President and Chief Scientific Officer of CoStim Pharmaceuticals, which was acquired by Novartis in 2014. From 2007 to 2013, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston.  Dr. Hicklin began his career at ImClone Systems where he held several positions of increasing responsibility from 1987 - 2007, most recently serving as Vice President of Experimental Therapeutics. Dr. Hicklin’s team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), necitumumab, and other cancer therapies that were acquired by Eli Lilly in 2008. Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his Master’s and PhD in Microbiology & Immunology from New York Medical College and earned his BS from the University of Iowa.

David Cordo - Chief Financial Officer

Prior to serving as interim CFO for VC-backed life sciences companies including Potenza Therapeutics, Dicerna Pharmaceuticals, Epizyme, Mitobridge, Semma Therapeutics, and TransForm Pharmaceuticals, Mr. Cordo served as Treasurer of Millennium Pharmaceuticals and in finance senior management positions at Biogen Idec. He is a Certified Public Accountant, holds an MBA from Nichols College and a B.S./B.A. degree from Stonehill College.

Gregory Sieczkiewicz, JD, PhD - Chief IP Counsel

Gregory Sieczkiewicz also serves as Managing Director and Chief IP Counsel at MPM Capital. Dr. Sieczkiewicz has provided in-house leadership as the architect of IP strategy in over a dozen venture-backed life sciences companies. He previously practiced IP prosecution and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Prior to entering the field of patent law, Dr. Sieczkiewicz completed his post-doctoral fellowship at the National Cancer Institute. He graduated from the College of the Holy Cross with an A.B. in Biology, received his PhD in cell, molecular and developmental biology from Tufts University School of Medicine and graduated magna cum laude from the evening program of Suffolk University Law School.

Cynthia Seidel-Dugan, PhD - Senior Vice President, Research

Prior to joining Potenza Therapeutics in 2014, Cynthia Seidel-Dugan served as Vice President, Biology of CoStim Pharmaceuticals. From 2005 to 2012 she served as Executive Director, Discovery Biology and New Targets, Oncology at Schering-Plough and Merck & Co. She also worked at Exelixis and ARIAD Pharmaceuticals. Teams she has led or worked with supported the discovery and clinical development of multiple small molecule and antibody therapeutics for oncology indications. Cindy has co-authored over 15 peer-reviewed publications and is an inventor on 7 issued and pending patents. Dr. Seidel-Dugan completed her post-doctoral studies at University of Pennsylvania in the laboratory of Dr. Joan Brugge, received her PhD in micro/molecular biology from the University of Pennsylvania and a B.S., biology from the College of William and Mary.

Reid J. Leonard, PhD - Senior Vice President, Corporate Development

Prior to joining Potenza Therapeutics in 2014, Reid Leonard retired from Merck & Co, where he progressed from scientist, to business development and licensing executive, to leading the strategic venture fund of Merck Research Laboratories. A graduate of Brandeis University (B.A., biology & psychology), and Purdue University (PhD, neuroscience), Dr. Leonard completed his academic training as a postdoctoral fellow in molecular pharmacology and physiology at the California Institute of Technology in the laboratories of Norman Davidson and Henry Lester.

Eileen McCullough - Senior Director, Project and Program Management

Prior to joining Potenza Therapeutics in 2015, Eileen was an external advisor to the strategic venture fund of Merck Research Laboratories. She also served as interim senior management for several healthcare startups. Before starting her career with startups, she worked for the biologics division of Medtronic. She has led the launch of over 15 products. She received her MBA from Harvard Business School and an AB, chemistry from Amherst College.